Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT)

The identification of four Consensus Molecular Subtypes (CMS1-4) of colorectal cancer forms a new paradigm for the design and evaluation of subtype-directed therapeutic strategies. The most aggressive subtype - CMS4 - has the highest chance of disease recurrence. Novel adjuvant therapies for patient...

Full description

Saved in:

Bibliographic Details
Published in:	BMC cancer Vol. 17; no. 1; p. 282
Main Authors:	Ubink, I, Bloemendal, H J, Elias, S G, Brink, M A, Schwartz, M P, Holierhoek, Y C W, Verheijen, P M, Boerman, A W, Mathijssen, R H J, de Leng, W W J, de Weger, R A, van Grevenstein, W M U, Koopman, M, Lolkema, M P, Kranenburg, O, Borel Rinkes, I H M
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 19-04-2017 BioMed Central BMC
Subjects:	Adjuvant treatment Antineoplastic Agents - therapeutic use Cancer Cancer therapies Care and treatment Chemotherapy Chemotherapy, Adjuvant Clinical trials Clinical Trials, Phase II as Topic Colon cancer Colon carcinoma Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Gene expression Growth factor receptors Humans Imatinib Imatinib Mesylate - therapeutic use Kinases Medical prognosis Mesenchyme Metastases Metastasis Multicenter Studies as Topic Platelet-derived growth factor Platelet-derived growth factor receptors Pre-operative window Preoperative Period Prognosis Proof-of-concept Research Design Ribonucleic acid RNA RNA sequencing Studies Study Protocol Surgery Targeted cancer therapy Targeted therapy Treatment Outcome Tumors RNA sequencing Imatinib Pre-operative window Proof-of-concept Colon carcinoma Targeted therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!